ReviewMedicine and pharmacy reports2021
Coronavirus (COVID-19) infection - impact on cardiovascular system.
Review in Medicine and pharmacy reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- COVID-19 and cardiovascular complications: updates of emergency medicine.Emergency and critical care medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This review aimed to explain novel coronavirus (COVID-19) infection impact on cardiovascular system and patients management in community and primary care settings. Method: Literature search and review limited to 2020 of published papers identified dealing with Coronavirus and cardiovascular disease. Results: Coronavirus is a large family of positive-sense, enveloped, single-stranded RNA viruses that belong to the Conclusion: In patients with underlying cardiovascular diseases, aggressive treatment for COVID-19 should be considered and clinicians should be aware of the significantly increased risk of serious infection and worse prognosis in this patient group. New evidence and studies are continually emerging and will confirm or refute our current understanding about COVID-19 impact. Primary care practitioners are urged to continue to monitor the evolving evidence to appropriately manage their patients who are at risk of, or currently diagnosed with cardiovascular conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.